Ironwood Pharmaceuticals: One Trial Stands Between Bargain And Bust

Solomon Oshabaheebwa 35 Followers Follow Summary Ironwood Pharmaceuticals trades at a 40% discount to its risk-adjusted sum-of-the-parts valuation, anchored by LINZESS and apraglutide. I assign a 'Buy' rating on IRWD and a $6.3 price target, citing a margin of safety, but I also warn of a binary risk tied to apraglutide's pivotal trial. LINZESS faces a patent cliff in 2029, with revenue projected to decay rapidly following the entry of generic products. Apraglutide's launch is delayed until 2029 pending STARS-2 trial results; success could offset LINZESS decline, but failure would severely impair equity value. Klaus Vedfelt/DigitalVision via Getty Images Ironwood Pharmaceuticals, Inc. ( IRWD ) is currently priced at a 40% discount to the risk-adjusted sum-of-the-parts value. In this article, I break down the valuation of IRWD's two major assets, LINZESS® (linaclotide) and apraglutide, and show that their combined value is This article was written by Solomon Oshabaheebwa 35 Followers Follow I am an independent investor and analyst with a background in Biomedical Engineering. Currently pursuing a PhD in the field, I leverage my research skills and biotech expertise to critically assess publicly traded companies, focusing on their fundamentals. While my expertise is centered in the biotech sector, I am open to exploring other ideas within my circle of competence. I seek to identify opportunities that are often overlooked by the broader market. My investment style is inspired by value investors like Warren Buffett, Charlie Munger, Howard Marks, Mohnish Pabrai, and other similar thinkers. My articles are a collection of my research notes and investment ideas, discovered through my ongoing search for personal investment opportunities. I view publishing these thoughts as a valuable way to engage with the broader investment community, receive feedback, and ultimately refine my investment approach. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.